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Summary Prostate cancer is the second most common malignancy in men in the UK. The disease is unpredictable in its behaviour and, at
present, no single investigative method allows clinicians to differentiate between tumours that will progress and those that will remain
quiescent. There is an increasing need for novel means to predict prognosis and outcome of the disease. The aim of this study was to assess
the value of artificial neural networks in predicting outcome in prostate cancer in comparison with statistical methods, using a combination of
conventional and experimental biological markers. Forty-one patients with different stages and grades of prostate cancer undergoing a variety
of treatments were analysed. Artificial neural networks were used as follows: eight input neurons consisting of six conventional factors (age,
stage, bone scan findings, grade, serum PSA, treatment) and two experimental markers (immunostaining for bcl-2 and p53, which are both
apoptosis-regulating genes). Twenty-one patients were used for training and 20 for testing. A total of 80% of the patients were correctly
classified regarding outcome using the combination of factors. When both bcl-2 and p53 immunoreactivity were excluded from the analysis,
correct prediction of the outcome was achieved in only 60% of the patients (P = 0.0032). This study was able to demonstrate the value of
artificial neural networks in the analysis of prognostic markers in prostate cancer. In addition, the potential for using this technology to
evaluate novel markers is highlighted. Further large-scale analyses are required to incorporate this methodology into routine clinical practice.
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Prostate cancer is the second most common malignancy in men in
the UK, with approximately 14 000 new cases diagnosed and 9000
men dying from the disease every year (Office of Population
Censuses and Surveys OPCS, 1996). Although tumour stage and
volume, serum prostate-specific antigen levels, histopathological
grading and DNA tumour ploidy status have all been shown to
correlate with prognosis and survival, none of these methods can
predict reliably tumours that are likely to progress and metastasize.
In addition to established clinical prognostic markers, several new
factors are emerging that may have a varying degree ofsignificance
in predicting outcome. Among these novel experimental markers
are the genes regulating programmed cell death, otherwise known
as apoptosis. These include the tumour-suppressor gene p53 and
the proto-oncogene bcl-2. It is now evident that the effects of
androgen suppression in prostate cancer are mediated via apo-
ptosis. Deregulation ofthe genetic pathway leading to programmed
cell death may confer hormone-resistant prostate cancer, which is
incurable. Our group has demonstrated previously that the combi-
nation of bcl-2 overexpression and p53 nuclear accumulation
by immunohistochemistry correlates strongly with hormone-
refractory prostate cancer (Apakama et al, 1996; Byrne et al, 1997).
In the present study, we have attempted to incorporate experi-
mental with conventional markers to assess the sensitivity of
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neural networks in predicting outcome following appropriate
training. The results were compared with those obtained from
conventional statistical methods.
Artificial neural networks
Artificial neural networks (ANNs) are parallel information-
processing structures that attempt to emulate certain performance
characteristics of the biological neural system (Cross et al, 1995;
Naguib and Sherbet, 1997). An ANN consists of many processing
elements (neurons), which are organized into groups called layers.
A typical network consists of a sequence of layers successively
connected by full or random connections. There are typically two
layers with connection to the outside world: an input layer where
data is presented to the network and an output layer that holds the
response ofthe network to a given input. The mathematical model
of an artificial neuron is shown in Figure 1, whereas Figure 2
shows a generic feed-forward fully interconnected ANN.
The application of such networks represents a major change in
the traditional approach to problem solving. As is the case with the
human brain, it is no longer necessary to know a formal mathemat-
ical model of the classification or recognition problem and then
perform the test and recall phases based on this knowledge.
Instead, if a comprehensive training set and a suitable network
architecture are devised, then an error back-propagation algorithm
can be used to adapt network parameters to obtain the
input-output relationships required. The solution is obtained
through experimentation and simulation rather than through a
rigorous and formal approach to the problem, as is the case with
existing statistical methods currently applied in many cancer
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research and survival analysis studies. In this study we have used
ANNs in an attempt to assess the prognostic value of new experi-
mental factors combined with conventional clinical criteria in
patients with different stages ofprostate cancer. A number of such
markers are analysed in relation to patient outcome. The results
and implications of using ANNs in assessing multiple experi-
mental markers in prostate cancer are discussed.
PATIENTS AND METHODS
Patients
Forty-one men with histologically proven prostate cancer were
studied. Their age ranged from 47 to 86 years (median 73 years).
Twenty men (49%) had evidence of skeletal metastasis as demon-
strated by technetium-99m isotope bone scanning, and received
hormone manipulation. Eleven patients (27%) had clinically local-
ized disease and received either 'watchful waiting' or external
beam irradiation. The remaining ten men (24%) had locally
advanced cancers and received either radiotherapy or hormone
manipulation. Follow-up ranged from 34 to 68 months (median 56
months). To date, 25 patients have died from the disease. Ofthose,
five had not responded to initial treatment and 20 developed resis-
tant prostate cancer. The remaining 16 patients were alive and well
at the last follow-up.
Methods
Immunohistochemistry
Immunohistochemical staining of representative tissue sections
was performed using specific antibodies against bcl-2 (Dako, UK)
and p53 (DO-7, Dako) as described previously (Apakama et al,
1996). One thousand cells were counted to detect p53 nuclear
protein accumulation and bcl-2 protein overexpression. The inten-
sity of nuclear p53 protein accumulation was classified according
to the percentage ofcells with strong nuclear staining: '+', 5-25%;
'++', 26-75%; '+++', > 75%. Intensity ofcytoplasmic staining for
bc1-2 in tumour cells was categorized as '+', focal areas of staining
(< 5%); '++', diffuse staining (5-50%); '+++', diffuse staining
(> 50%). Positive controls matching the fixation protocol of the
test material were used. These were colorectal carcinoma for p53
and tonsil for bcl-2. In addition, basal cells in benign prostatic
glands and lymphocytes, which are known to stain positively for
bcl-2, were used as internal positive control. Negative controls
were performed by omitting the primary antibody in each case.
ANNs
The patients were randomly subdivided into training and test sets
consisting of 21 and 20 patients respectively. The analysis was
simulated on the NeuralWorks Professional II/Plus software
package (NeuralWare, Pittsburgh, PA, USA). The structure used is
of the feed-forward type and based on Kohonen's self-organizing
maps and the back-propagation of errors.
A total of eight input neurons was considered. They consist of
six conventional factors: patient's age, tumour stage (TI-T4)
(Schroeder et al, 1992), skeletal metastasis (MO-M1), Gleason
score, serum PSA and treatment (hormonal, external beam irradia-
tion or watchful waiting), and two experimental markers: p53 and
bcl-2 immunostaining. Three output neurons consisting of
different outcomes were used: (1) no response to treatment; (2)
relapse following initial successful treatment and/or disease
progression in untreated patients; and (3) sustained complete
response to treatment or no progression in untreated patients.
Statistical analysis
In order to evaluate ANNs, the data were analysed in parallel with
conventional multivariate statistics. The method used was a
multiple discriminant analysis (MDA). This was performed using
the statistical package Unistat 4.5 (Unistat, UK). Probabilities
were tested using Fisher's exact and McNemar's tests; P-values
less than 0.05 were considered statistically significant.
RESULTS
Immunohistochemistry
Twenty-three patients (56%) had positive staining for p53 and 35
(85%) had positive staining for bcl-2. Whereas bcl-2 staining was
not significantly related to histological grade or other clinical para-
meters, p53 staining was related to both histological grade and
clinical stage at diagnosis. There were no significant differences
between scores of p53 and bcl-2 staining and these parameters
(data not shown). Sixteen of 25 patients (64%) who had hormone-
refractory disease, either at the onset of treatment (n = 5) or within
18 months from initiation of hormone manipulation (n = 20), were
p53 positive, compared with 7 of 16 (44%) who had a sustained
response to treatment and were alive and well at follow-up
(Fisher's exact test, P = 0.0069). Twenty-two of 25 patients (88%)
with hormone resistance and 13 of 16 (81%) who are alive and
well were bcl-2 positive with no statistically significant difference
between these groups. Thirteen of the 25 patients (52%) who
escaped hormonal control were positive for both bcl-2 and p53
compared with 4 of the 16 patients (25%) who are alive and well
(Fisher's exact test, P < 0.0001). Patient outcome was correlated
with immunohistochemical findings. Prediction of outcome was
tested using conventional criteria alone and in combination with
immunoreactivity for p53 and/or bcl-2.
Neural network analysis
Four separate analyses were performed. In the first, all eight input
markers were considered and the outcomes predicted for the test set
of 20 patients. To analyse the respective significance of the
experimental markers (p53 and bcl-2) on the results, they were each
omitted in turn and the network repeatedly simulated and tested.
Finally, in order to assess the combined impact of those two experi-
mental markers on outcome prediction, they were both omitted from
the set of input neurons and the network was simulated and vali-
dated on the test set of 20 patients. Results of all the above analyses
are given in the confusion matrices of Tables 1-4, along with their
kappa (K) statistics and 95% confidence intervals (CIs).
Comparison of ANNs with statistical analysis
Multiple discriminant analysis was used for each of the four
combinations of data examined by ANNs. In all the cases investi-
gated, except the case in which both p53 and bcl-2 were omitted
from the analysis and conventional criteria were used alone, the
ANN performance in predicting outcome was superior by a value
of 5% to that of MDA as shown in Table 5. Although this may not
have reached statistical significance in the cases in which p53 and
bcl-2 were alternately omitted, statistical significance was attained
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Table 1 Confusion matrix showing the relationship between actual and ANN predicted outcomes for the case when all markers are considered Kappa (K)
statistics with 95% confidence intervals (Cl) are also given
Actual outcome
ANN-predicted outcome No response Sustained Relapsed
to treatment to treatment response Total
No response to treatment 1 0 0 1
Sustained response to treatment 0 8 3 11
Relapsed 1 0 7 8
Total 2 8 10 20
ANN prediction accuracy, 80%; K, 0.6522; Cl, 0.3585 < > 0.9459 (P< 0.00001).
Table 2 Confusion matrix showing the relationship between actual and ANN predicted outcomes for the case when p53 is omitted. Kappa (K) statistics with
95% confidence intervals (Cl) are also given
Actual outcome
ANN-predicted outcome No response Sustained Relapsed
to treatment to treatment response Total
No response to treatment 0 0 0 0
Sustained response to treatment 0 6 2 8
Relapsed 2 2 8 12
Total 2 8 10 20
ANN prediction accuracy, 70%; K, 0.4444; Cl, 0.0992 < > 0.7897 (P = 0.0058).
Table 3 Confusion matrix showing the relationship between actual and ANN predicted outcomes for the case when bcl-2 is omitted. Kappa (K) statistics with
95% confidence intervals (Cl) are also given
Actual outcome
ANN-predicted outcome No response Sustained Relapsed Total
to treatment to treatment response
No response to treatment 0 0 0 0
Sustained response to treatment 0 7 4 11
Relapsed 2 1 6 9
Total 2 8 10 20
ANN prediction accuracy, 65%; K, 0.3694; Cl = 0.0289 < > 0.7099 (P = 0.0167).
Table 4 Confusion matrix showing the relationship between actual and ANN predicted outcomes for the case when both p53 and bcl-2 are omitted from the
analysis. Kappa (K) statistics with 95% confidence intervals (Cl) are also given
Actual outcome
ANN-predicted outcome No response Sustained Relapsed Total
to treatment to treatment response
No response to treatment 1 0 1 2
Sustained response to treatment 0 8 6 14
Relapsed 1 0 3 4
Total 2 8 10 20
ANN prediction accuracy, 60%, K, 0.3443; Cl, 0.0560 < > 0.6325 (P = 0.0096).
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Table 5 Comparison of ANNs with conventional statistics in predicting
outcome
All markers p53 bcl-2 p53/bc1-2
omitted omitted omitted
ANN accuracy 80% 70% 65% 60%
MDA accuracy 75% 65% 60% 65%
McNemar's two-tail
probability test 0.0192 0.1671 0.3593 0.3833
ANN, artificial neural network; MDA, multiple discriminant analysis.
for the case in which all markers were considered (McNemar's
test, P = 0.0096).
DISCUSSION
Prostate cancer is a common malignancy that is unpredictable in
its behaviour. Whereas many tumours will remain quiescent and
clinically unimportant, some will progress to advanced and
metastatic disease resulting in considerable morbidity and
mortality. The biggest dilemma in the management of this malig-
nancy is to discriminate cancers that will progress from those that
will remain at a latent stage. It is disconcerting that, to date, no
reliable method to achieve this discrimination exists. The problem
is compounded by controversies surrounding the efficacy of
aggressive treatment, particularly in the early stages ofthe disease.
At present, the most commonly used criteria influencing clinical
decision-making in treating prostate cancer are a combination of:
patient's age and life expectancy, tumour stage and grade, and
serum PSA levels. In addition to these conventional criteria, novel
prognostic markers are emerging continuously and are being
assessed as additional information to improve management. These
markers, in combination with conventional parameters, are tradi-
tionally evaluated in large observational studies of patients with
long term follow-up periods using statistical analysis.
Several statistical methods such as Cox's proportional hazards
(Cox, 1972) and logistic regression (Lilford and Braunholtz, 1996)
have been employed to study survival patterns in different cohorts
of cancer patients. Such approaches are valuable, but suffer from a
number of limitations including: (1) the degree of impact of any
prognostic marker on the analysis has to be assessed a priori, and
(2) any outcome produced by the analysis cannot always apply to
individual cases.
ANNs, on the otherhand, have the ability to predict outcome for
individual patients through a thorough and generalized analysis of
previous patient trends and, perhaps more importantly, patterns of
tumour-associated parameters can be examined in ways that
conventional statistics do not consider. The ANN approach to
medical information processing has been used in a number of
applications such as anaesthesiology (Narus et al, 1995), radiology
(Wu et al, 1995), cardiology (Keem et al, 1995; Andrae, 1996),
psychiatry (Dumitra et al, 1995) and neurology (Moreno et al,
1995). This approach has several benefits including the ability to:
(a) train by examples instead of rules; (b) be automated; and (c)
eliminate issues associated with human fatigue, habits and subjec-
tive decision-making processes. Furthermore, it enables rapid and
flexible identification ofprominent markers and provides outcome
on an individual basis (Naguib et al, 1996). In human cancer,
ANNs have been used in a number of studies including the early
Figure 1 Mathematical model of an artificial neuron. The biological soma is
represented by the processing elements. Inputs to the processing element
represent the dendrites and the effects of the synaptic gap in the biological
neuron are represented by the weights on the connections between inputs









Figure 2 Artificial neural network structure, comprising of the input neurons
through which the prognostic factors are presented, followed by the hidden
layers, which provide the necessary non-linearity, and the output neurons,
which deliver the outcomes of the analysis.
detection and diagnosis of breast cancer (De Laurentiis and
Ravdin, 1994), the classification of normal, premalignant and
malignant oral smears (Brickley et al, 1996) and the comparison of
prediction accuracy of the TNM staging system with that of ANN
methods (Burke et al, 1997).
In prostate cancer, recent studies have evaluated the use of
ANNs in diagnosis and the prediction of recurrence following
radical surgery (Snow et al, 1994; Barnhill et al, 1997; Stamey et
al, 1997). The results showed high sensitivity and specificity rates
in predicting biopsy results in men with suspected prostate cancer,
and recurrence following radical prostatectomy. The analysis,
however, was based on variables consisting of well established
and conventional clinical and biochemical criteria. Other studies
involved the use of hybrid neural and statistical classifier systems
for the histopathological grading ofprostatic lesions (Stotzka et al,
1995) and the identification of predictors ofgeneral quality of life
in patients with benign prostate hyperplasia or prostate cancer
(Krongrad et al, 1997).
In the present study we have evaluated the ability of ANNs to
assess novel prognostic markers, in addition to established clinical
and biochemical parameters. These experimental markers (p53 and
bcl-2 immunopositivity) have been studied extensively by a multi-
plicity of workers including our own group. In the current series of
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patients, results ofimmunostaining confirmed the previously shown
correlation between hormone-refractory disease and the combina-
tion ofp53 and bcl-2 positivity. In order to evaluate the performance
of ANNs, we have compared the results of the analyses with
conventional statistical methods. This comparison has demonstrated
the superiority of ANNs over statistics using MDA and McNemar's
tests, in three ofthe four investigations performed. It is worth noting
that, ofthese three investigations, in the case in which both conven-
tional and experimental markers were considered, improvement in
accuracy of prediction by ANNs was statistically significant (P =
0.0096). In addition, when Fisher's exact test was used to assess
ANNs in the same situation, when both bcl-2 and p53 were included
80% accuracy of prediction was achieved compared with 60%
accuracy when they were both omitted (P = 0.0032). When p53 or
bcl-2 was omitted, accuracy was reduced but this did not reach
statistical significance (Tables 1-4).
In summary, despite the small number of patients included in
this pilot study, we have demonstrated the ability of ANNs to
assess prognostic markers objectively in prostate cancer. ANNs
may represent a useful adjunct to conventional statistical methods
in the evaluation of an ever increasing number of experimental
markers reported by researchers investigating the biology of this
common malignancy. Further work using large cohorts of patients
is warranted in order to define the role of ANNs in cancer data
analysis, with a view to bringing this technology into routine
clinical practice.
REFERENCES
Andrae A ( 1996) Neural networks and early diagnosis of imiyocardial itnfarctioni.
Lkincet 347: 41)7-4(08
Apakamiia 1. Robinson MC. Walter NM. Charlton RG, Royds JA. Fuller CE. Neal DE
and Hamiidy FC (1996) bcl-2 overexpression comubined with p53 protein
accuLmulation correlates with hormone-refractory prostate cancer. Br J Concer
74: 1258-1262
Barnhill SD. Stamey TA, Zhang Z. Zhang H and Madyastha KR (1997) The ability
of the ProstAsureTsl index to identify prostate cancer patients with low canlcer
Volumies and a high potential for cure. J Ur-ol 157: 241 A
Brickley MR. Cowpe JG and Shepherd JP (1996) Performanice of a comiiputer
simtlulated neu-al nietwork to categorise normal. premalignant and malignant
Burke HB. Goodmiian PH, Rosen DB. Henson DE, Weinstein JN. Harrell Jr FE.
Marks JR, Winchester DP and Bostwick DG ( 1997) Artificial neural networks
improve the accuracy of cancer survival prediction. Cancer 79: 857-862
Byrne RL. Horne CHW. Robinson MC, Autzen P, Apakama 1, Bishop RI. Neal DE
and Hamdy FC (1997) The expression of WAF-1, p53 and bcl-2 in prostatic
adenocarcinoma. BrJ UCol 79: 190-195
Cox DR (1972) Regression models and life-tables. J Roy Stat Soc (B) 34: 187-20(1
Cross SS, Harrison RF and Kennedy RL (1995) Introduction to neural networks.
La,tcet 346: 1075-1079
De Laurentiis M and Ravdin PM (1994) Survival analysis ofcensored data: neural
network anialysis detection ofcomplex interactions between variables. Breo.st
Caitce- Re.s Tr-et 32: 113-1I 8
Dumitra A, Radulescu E and Lazarescu V (1995) Improved classification of
psychiatric mood disorders using a feedforward neural network. Mediift 8:
818-822
Keem S. Meadows H and Kemp H (1995) Hierarchical nieural networks in
quantitative coronary arteriography. Proc IEEE Ilot Conif'on ANNs 459-464
Krongrad A. Granville LJ. Burke MA, Golden RM, Lai S. Cho L and Niederberger
CS ( 1997) Predictors of general quality of life in patients with benign prostate
hyperplasia or prostate cancer. J Ur-ol 157: 534-538
Lilford RJ and Braunholtz D (1996) The statistical basis of public policy: a paradigm
shift is overdue. Br Mecd J 313: 603-607
Moreno L. Pihero JD. Sanchez JL. Manas J, Acosta L and Hamilton A (1995) Brain
maturation using neural classifier. IEEE Troni.s Biontied EItg 42: 428-432
Naguib RNG and Sherbet GV ( 1997) Artificial neural networks in cancer research.
Pathobiology 65: 129-139
Naguib RNG, Adams AE. Horne CHW, Angus B. Sherbet GV anid Lennard TWJ
(1996) The detection of nodal metastasis in breast cancer using neural network
techniques. Pliss Meos 17: 297-303
Narus SP. Kiick K and Westenskow DR (1995) Intelligent monitor for an anaesthesia
breathing circuit. ProcAItI,t SvYmp Cont7p Appl Med Ca-e 96-100
Office of Population Censuses and Surveys ( 1996) Ca1ncer-Stti.stic.s. Registcitionis
1991 Enigltinad aild Wailes. Series MBI No. 21). HMSO: London
Schroeder F. Hermiianek P, Denis L. Fair W, Gospodarowick MK and Pavone-
Macaluso M ( 1992) The TNM classification of prostate cancer. Prostwe 4:
129-138
Snow PB. Smith DS and Catalona WJ (1994) Artificial neural networks in the
diagnosis and prognosis of prostate cancer: a pilot study. J U-ol 152:
19923-1926
Stamey TA. Barnhill SD. Zhang Z. Madyastha KR and Zhang H (1997) A neural
network (ProstAsure '') with high sensitivity anid specificity for diagnosing
prostate cancer in mnen with a PSA < 4.0 ng/ml. J CUo-) 157: 1425A
Stotzka R, Minner R. Bartels PH and Thompson D (1995) A hybrid neural and
statistical classifier systemii for histopathologic grading of prostatic lesions.
Aitalvt Qutl,lt Cvtol Histol 17: 204-218
Wu YC. Doi K and Giger ML (1995) Detection of lung nodules in digital chest
radiographs using artificial neural networks: a pilot study. J Dig Imai1ig 8: 88-94
British Journal of Cancer (1998) 78(2), 246-250 C Cancer Research Campaign 1998